6610-31-7

Usage

Uses

Used in Chemical Reactions:
4-Butyl-3-thiosemicarbazide is used as a reactive compound in various chemical reactions for [application reason]. Its reactivity allows it to participate in a wide range of chemical processes, making it a valuable component in the synthesis of other compounds.
Used in Industrial Processes:
In the industrial sector, 4-Butyl-3-thiosemicarbazide is used as a key component in the production of certain chemicals for [application reason]. Its presence in these processes is crucial for achieving the desired outcomes and final products.
Used in Scientific Research:
4-Butyl-3-thiosemicarbazide is employed as a research compound in scientific studies for [application reason]. Its unique properties and reactivity make it an interesting subject for exploration in various fields of chemistry and related sciences.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-Butyl-3-thiosemicarbazide is used as a building block in the development of new drugs for [application reason]. Its potential in drug synthesis and its ability to form complex molecules make it a promising candidate for creating novel therapeutic agents.

InChI:InChI=1/C5H13N3S/c1-2-3-4-7-5(9)8-6/h2-4,6H2,1H3,(H2,7,8,9)

Upstream product

• 75-15-0 carbon disulfide 
• 109-73-9 N-butylamine 
• 60448-30-8 N-butylthioformamide 
• 628-30-8 n-Propyl isothiocyanate 
• 64573-65-5 butyl-thiocarbamic acid 
• 56134-96-4 ethyl butyldithiocarbamate 
• 592-82-5 butyl isothiocyanate 

Downstream Products

• 51984-12-4 (E)-4-butyl-1-(pyridin-2-ylmethylene)thiosemicarbazide 
• 6334-22-1 4-methoxy-benzaldehyde-(4-butyl thiosemicarbazone) 
• 73418-27-6 butyl-[5-(2-phenyl-quinolin-4-yl)-[1,3,4]thiadiazol-2-yl]-amine 
• 149381-60-2 C₁₈H₂₅N₅OS 
• 820246-84-2 C₂₁H₂₃N₅OS 
• 66962-52-5 5-butylamino-3H-[1,3,4]thiadiazole-2-thione 
• 25976-45-8 4-(5-butylamino-[1,3,4]thiadiazol-2-yl)-benzenesulfonamide 
• 1019283-20-5 C₁₅H₂₁N₃S 
• 67644-80-8 3-butyl-2-(4-hydroxy-naphthalen-1-ylazo)-4,5-diphenyl-thiazolium betaine 
• 67644-68-2 3-butyl-4,5-diphenyl-3H-thiazol-2-one hydrazone 
• 67644-73-9 4-nitro-benzaldehyde (3-butyl-4,5-diphenyl-3H-thiazol-2-ylidene)-hydrazone 
• 67644-78-4 3-butyl-4,5-diphenyl-3H-thiazol-2-one isopropylidenehydrazone 
• 131533-05-6 3-(4-Bromo-phenyl)-2-{[3-butyl-4-oxo-thiazolidin-(2Z)-ylidene]-hydrazonomethyl}-3H-quinazolin-4-one 
• 77523-91-2 3-Methyl-5-phenyl-pyrazole-1-carboxylic acid butylamide 

Relevant academic research and scientific papers

CERTAIN NEW 4-(2-((5-(SUBSTITUTEDAMINO)-1,3,4-THIADIAZOLE-2-YL)THIO)ACETYL)BENZENESULPHONEAMIDE DERIVATIVES AND A METHOD FOR THE SYNTHESIS OF SAID DERIVATIVES

The invention relates to a certain new 4-(2-((5-(substitutedamino)-1,3,4-thiadiazole-2-yl)thio)acetyl)benzenesulphonamide derivatives for use in pharmaceutics, chemical and pharmaceutical industry, and to a method for the synthesis of said derivatives.

Diaryl-substituted thiosemicarbazone: A potent scaffold for the development of New Delhi metallo-β-lactamase-1 inhibitors

The superbug infection caused by New Delhi metallo-β-lactamase (NDM-1) has become an emerging public health threat. Inhibition of NDM-1 has proven challenging due to its shuttling between pathogenic bacteria. A potent scaffold, diaryl-substituted thiosemicarbazone, was constructed and assayed with metallo-β-lactamases (MβLs). The obtained twenty-six molecules specifically inhibited NDM-1 with IC50 0.038–34.7 μM range (except 1e, 2e, and 3d), and 1c is the most potent inhibitor (IC50 = 0.038 μM). The structure-activity relationship of synthetic thiosemicarbazones revealed that the diaryl-substitutes, specifically 2-pyridine and 2-hydroxylbenzene improved inhibitory activities of the inhibitors. The thiosemicarbazones exhibited synergistic antimycobacterial actions against E. coli-NDM-1, resulted a 2–512-fold reduction in MIC of meropenem, while 1c restored 16–256-, 16-, and 2-fold activity of the antibiotic on clinical isolates ECs, K. pneumonia and P. aeruginosa harboring NDM-1, respectively. Also, mice experiments showed that 1c had a synergistic antibacterial ability with meropenem, reduced the bacterial load clinical isolate EC08 in the spleen and liver. This work provided a highly promising scaffold for the development of NDM-1 inhibitors.

Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma

A series of novel 3-indolinone-thiazolidinones and oxazolidinones 4a-k was synthesized via molecular hybridization approach and sequentially evaluated to explore its cytotoxic activity. The cytotoxicity screening pointed toward the N-cyclohexyl thiazolidinone derivative 4f that revealed promising renal cytotoxicity against CAKI-1 and UO-31 renal cancer cell lines with IC50 values 4.74 and 3.99 μM, respectively, which were comparable to those of sunitinib along with good safety threshold against normal renal cells. Further emphasis on compound 4f renal cytotoxicity was achieved via different enzyme assays and CAKI-1 and UO-31 cell cycle analysis. The results were supported by in silico studies to explore its physicochemical, pharmacokinetic and drug-likeness properties. Finally, compound 4f was subjected to an in vivo pharmacokinetic study through two different routes of administration showing excellent oral bioavailability. This research represents compound 4f as a promising candidate against renal cell carcinoma.

Synthesis, cytotoxicity, and in vivo antitumor activity study of parthenolide semicarbazones and thiosemicarbazones

Parthenolide is an important sesquiterpene lactone with potent anticancer activities. In order to further improve its biological activity, a series of parthenolide semicarbazone or thiosemicarbazone derivatives was synthesized and evaluated for their anti

Synthesis of new benzothiazole derivatives bearing thiadiazole as monoamine oxidase inhibitors

Monoamine oxidases (MAO) are enzymes that catalyze the oxidative deamination of monoamines such as dopamine, noradrenaline, adrenaline, and serotonin. Recent studies have shown that numerous benzothiazole derivatives exhibit hMAO inhibitory activity in the micromolar concentration range. In this study, a novel series of benzothiazole-thiadiazole (5a-5l) was synthesized and characterized their chemical structures by 1H-NMR, 13C-NMR, and Mass spectroscopy. These compounds were evaluated as inhibitors for types A and B MAO enzymes. Compounds 5f and 5l were the most active derivatives in the series with an IC50 values of 0.107 ± 0.003 and 0.128 ± 0.004, respectively. Furthermore, cytotoxicity of compounds 5f and 5l were investigated and found as non-cytotoxic.

Synthesis and characterization of a new series of thiadiazole derivatives as potential anticancer agents

Cancer is one of the most common causes of death in the world. Despite the importance of combating cancer in healthcare systems and research centers, toxicity in normal tissues and the low efficiency of anticancer drugs are major problems in chemotherapy. Nowadays the aim of many medical research projects is to discover new safer and more effective anticancer agents. 1,3,4-Thiadiazole compounds are important fragments in medicinal chemistry because of their wide range of biological activities, including anticancer activities. The aim of this study was to determine the capacity of newly synthesized 1,3,4-thiadiazole compounds as chemotherapeutic agents. The structures of the obtained compounds were elucidated using 1H-NMR, 13C-NMR and mass spectrometry. Although the thiadiazole derivatives did not prove to be significantly cytotoxic to the tumour tissue cultures, compound 4i showed activity against the C6 rat brain cancer cell line (IC50 0.097 mM) at the tested concentrations.

Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors-design, synthesis, biological evaluation and molecular modelling

Monoamine oxidases (MAOs) are important drug targets for the management of neurological disorders. Herein, a series of new 1,3,4-thiadiazole derivatives bearing various alkyl/arylamine moieties as MAO inhibitors were designed and synthesized. All of the compounds were more selective against hMAO-A than hMAO-B. The half maximal inhibitory concentration (IC50) values of most of the compounds were lower than that of the common drug moclobemide (IC50 = 4.664 μM) and compound 6b was proven to be the most active compound (IC50 = 0.060 μM). Moreover, it was seen that compound 6b showed a similar inhibition profile to that of clorgyline (IC50 = 0.048 μM). The inhibition profile was found to be reversible and competitive for compound 6b with MAO-A selectivity. Molecular modelling studies aided in the understanding of the interaction modes between compound 6b and MAO-A. Furthermore, this compound was predicted to have a good pharmacokinetic profile and high BBB penetration. Therefore, such compounds are of interest towards developing new MAO inhibitors.

Dioxomolybdenum(VI) complexes of S-methyl-5-bromosalicylidene-N-alkyl substituted thiosemicarbazones: Synthesis, catalase inhibition and antioxidant activities

We synthesized a series of S-methyl-5-bromosalicylidene-N-alkyl substituted thiosemicarbazones and their cis-dioxomolybdenum(VI) complexes having long alkyl chains (propyl, butyl, pentyl, hexyl, and octyl) on thioamide nitrogen. The compounds were characterized by using analytical and spectroscopic methods. The structure of the complex with pentyl group (complex 3) as a representative molecule was determined by X-ray single-crystal diffraction method. The free ligand and their dioxomolybdenum(VI) complexes have been tested for in vitro antioxidant capacity by reduction of copper (II) neocuproine (Cu(II)-Nc) using the CUPRAC (CUPric Reducing Antioxidant Capacity) method. The ligands exhibited more potent in vitro antioxidant capacity than that of the complexes. The obtained trolox equivalent antioxidant capacity (TEAC) value of complex 1 (TEACCUPRAC = 0.73) was higher than those of other complexes. Furthermore, the catalase activity and reactive oxygen species (ROS) scavenging ability of the free ligands and their complexes were determined, showing that complex 1 had significant scavenging activity for ROS.

Synthesis, characterization and biological evaluation of novel 1-N-substituted thiocarbomoyl-3-ferrocenyl-2-pyrazoline derivatives

Some novel 1-N-substituted thiocarbomoyl-3-ferrocenyl-2-pyrazoline derivatives were synthesized and evaluated for in vitro antiamoebic activity against HM1:IMSS strain of Entamoeba histolytica. The results showed that most of the compounds exhibited promising activity (IC50 values in the range of 0.050-1.683 μM) than the reference drug metronidazole (IC50 = 1.78 μM). Active compounds were further screened for cytotoxicity against human embryonic kidney-293 (HEK-293) normal cell lines to ensure their toxic effect and the results revealed that active compounds were least toxic in the concentration range of 2.5-50 μM for 48 h and 2.5-25 μM for 72 h. At 100 μM for 48 h and at 50 μM for 72 h only four compounds 2c, 2h, 2k and 2l showed maximum viability and least cytotoxicity, respectively, concluding that all the screened compounds were least cytotoxic against human embryonic kidney-293 (HEK-293) normal cell lines in the concentration range of 2.5-50 and 2.5-25 μM.

Synthesis of some novel thiosemicarbazone derivatives having anti-cancer, anti-HIV as well as anti-bacterial activity

Some new thiosemicarbazones containing benzimidazole moiety have been synthesized and their ability to inhibit growth of 60 human cancer cell lines, in vitro replication of HIV virus strains as well as inhibition capacity for various bacterial strains have been evaluated. One compound 2-|l-(5-chloro-l//- benzimidazol-2-yl) ethylidene] N-phenylhydrazincarbothioamide (S2) (NSC 92491) has been selected for five dosage screening and shows remarkable anticancer activity along with good anti-HIV and anti-bacterial activities. The structures of all the compounds have been confirmed by FT-IR, NMR, and Mass spectra and by elemental analysis.